Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vyne Therapeutics Inc.
This is a double-blind, randomized, placebo-controlled study. Approximately 450 subjects will be randomized in a 1:1:1 ratio to receive daily oral doses of serlopitant 1 mg, 5 mg, or placebo for 6 weeks. During the screening period, subjects will be provided with an electronic device for recording electronic diary (eDiary) assessments throughout the study. This eDiary will be used to capture efficacy endpoint data and treatment information. At the Baseline visit, eligible subjects will be randomized, and study drug dispensed beginning with a loading dose of 3 tablets to be taken at bedtime that same day. Starting on Study Day 2, subjects will take one tablet per day at bedtime. Treatment will continue for 6 weeks. The primary efficacy endpoint will be assessed during Week 6. After completion of the 6-week treatment period, all subjects will enter a 4-week follow-up period.
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, age 13 years or older
Pruritus prior to and during the initial screening period
Diagnosis of atopic dermatitis
Judged to be in good health in the investigator's opinion
You may not be if
Prior treatment with study drug or similar drug
Pruritus due to another reason besides atopic dermatitis
Presence of any medical condition or disability that could interfere with study
History of hypersensitivity to serlopitant or any of its components
Currently pregnant or male partner of pregnant female
Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding